Navigation Links
SUTIMCo International Inc. to Attend 125th AOAC Annual Meeting
Date:9/12/2011

SANTA ANA, Calif., Sept. 12, 2011 /PRNewswire/ -- SUTIMCo International, Inc. (Pink Sheets: SUTI) is pleased to announce that it will send a corporate executive to the 125th Annual Meeting of The Association of Analytical Communities (AOAC) being held September 18-21 in New Orleans.   For over a century, AOAC has developed method validation programs for medical devices as well as proficiency testing and accreditation programs for laboratories.  The meeting is an international showcase for medical devices, attracting manufacturers and the customers who use their products in the lab, the plant and in the field.

SUTIMCo Vice President of Business Development Ed Ellsworth will attend the AOAC meeting to discuss the latest developments at CapWave Sensors, Inc. to produce Searchlight™ - a portable medical device initially serving the food safety testing market.  CapWave will make announcements soon regarding new strategic partnerships for product development that will accelerate time to market and contribute innovative technology to Searchlight.

AOAC is a global organization of 3,000 members whose scientific interests are in the agricultural, food, drug, and environmental science communities.  The annual meeting attracts some of the top firms in the industry including: Agilent Technologies, Thermo Scientific, Romer Labs, Biotage, Fisher Scientific and bioMerieux.

"Our presence at AOAC gives CapWave the opportunity to meet with prospective customers and introduce them to the Searchlight technology," stated Ed Ellsworth, Vice President of Business Development for SUTIMCo International, Inc.  "These are the experts in the labs.  I'm eager to get their input on our technology, learn precisely what they need and apply that to our product."

CapWave's Searchlight™ testing device is a rapid, sensitive, and portable amino chemistry platform based on the Enzyme-Linked Immuno-Sorbent Assay (ELISA) biochemical technique.  For food safety testing, Searchlight is capable of detecting toxins including E. coli, salmonella, listeria and campylobacter.  According to the Centers for Disease Control and Prevention (CDC), about 48 million people (1 in 6 Americans) get sick, 128,000 are hospitalized, and 3,000 die each year from foodborne diseases.

"As we bring strategic partners on board, both CapWave and the Searchlight device come into greater focus," Ellsworth said.  "As I share our story at AOAC, I believe the industry will be intrigued by this device.  More sensitivity, more speed, smaller sample sizes, it's an elegant solution."

The Searchlight™ device will first be available for food safety testing.  Product development for the veterinary and in vitro diagnostic markets is also being evaluated.

To set up a meeting with SUTIMCo at AOAC, please contact Boost Marketing at (407) 389-5900

For more information on CapWave Sensors, please visit; http://www.capwavesensors.com

For more information on SUTIMCo, its portfolio companies, and university partners, please visit; http://www.suti.com

About SUTIMCo International, Inc.:

SUTIMCo International Inc. is a holding company, which utilizes a unique and established platform to launch new technology enterprises based on world-class university research discoveries. SUTIMCo International through its wholly owned subsidiary SUTIMCo, Inc., provides experienced management to early stage companies, reducing risk and assuring the know-how in launching and growing a new company. In addition to this skilled management team, SUTIMCo can avail itself of the encyclopedic, informal knowledge of the inventor, his experience and his research team.

Safe Harbor: Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such statements about the Company's future expectations, including future revenues and earnings, technology efficacy and all other forward-looking statements be subject to the safe harbors created thereby. The Company is a development stage company who continues to be dependent upon outside capital to sustain its existence. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.

SUTIMCo International, Inc.
Investor Relations
407-389-5900


'/>"/>
SOURCE SUTIMCo International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New International Pharmaceutical Company Pro Bono Bio Launched Today
2. Emerging Pharmaceutical Market in India - Strategic Partnerships Between Domestic and International Pharmaceutical Players are the Driving Force
3. VWR International, LLC Acquires INTERNATIONAL P.B.I. S.p.A.
4. Bench International Expands Presence in Europe with Opening of Offices in Switzerland
5. Bacterin International to Present at Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
6. Spaulding Clinical Announces Strategic Partnership with Clinigene International, India for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clients
7. Chindex International, Inc. Announces Participation in Upcoming Investor Conferences
8. Pharmaceutics International, Inc. (Pii) Successfully Completes EMA and FDA Inspection
9. Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society
10. International St. Gallen Expert Panel Highlights Importance of Molecular Subtyping in Breast Cancer Treatment
11. PAREXEL International Reports Fourth Quarter and Fiscal Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017   Synthetic Biologics, ... company developing therapeutics designed to preserve the microbiome ... today confirmed plans to initiate a Phase 2b/3 ... reformulation of lovastatin lactone designed to reduce methane ... in the gut to treat the underlying cause ...
(Date:1/18/2017)... 18, 2017  Aprima Medical Software, a leading ... management (PM) and revenue cycle management (RCM) solutions ... a former reseller Healthcare Data Solutions (HDS) of ... Aprima will assume full support for HDS,s customers, ... practices across 15 states. Financial terms were not ...
(Date:1/18/2017)... 18, 2017   Spotlight Innovation Inc. ... plans, in the second quarter of 2017, to ... intended to provide relief from chronic pain, is ... It was developed under a licensing agreement with ... derived from snake venom. Additionally, Caretta Therapeutics has ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Connecticut Dermatology Group (CDG) is proud and excited to ... dermatologist. Dr. Kim brings an extensive background in cutting-edge dermatology care and research ... to welcome back Dr. Kim to the CDG team” said President and Managing Partner ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Infinity® Massage Chairs ... plan and implement new sales and marketing strategies. Grover comes with a total of ... 5 and a half years as Executive Vice President of Direct Sales at Traeger® ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of a ... about the benefits of fidgeting to relieve stress and anxiety. No one was ... Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on the ...
(Date:1/18/2017)... ... January 18, 2017 , ... The VA Maryland Health ... on a research project focused on multiple sclerosis (MS). Led by Christopher M. ... to control the disease without compromising normal immune function that often occurs during ...
(Date:1/18/2017)... FL (PRWEB) , ... January 18, 2017 , ... A ... fund raiser for Smile Train, an international charity that provides free surgery to poor ... of mine and in the past I have run to support the efforts of ...
Breaking Medicine News(10 mins):